ECZTEND

LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021

Ballerup, Denmark & Madison, N.J., United States: Interim analysis at 56 weeks from ECZTEND, an open-label extension trial, demonstrates sustainable…

Read More »